Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FVIII-R571S
- Development stage
- Preclinical
- Lead developer
- Children's Hospital of Philadelphia
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Factor VIII Aurora (FVIII-R571S) is a naturally occurring, hyperactive gain-of-function variant of coagulation factor VIII (FVIII). Originally identified in a patient with severe, recurrent thrombosis, the variant features an Arg571Ser (or Arg590Ser by HGVS nomenclature) mutation in the A2 domain of FVIII. Recombinant FVIII-R571S exhibits a 10- to 20-fold increased affinity for activated factor IX (FIXa), which enhances the assembly and function of the intrinsic tenase (Xase) complex. This increased affinity also protects the activated cofactor (FVIIIa) from A2-domain dissociation and activated protein C (APC)-mediated inactivation, conferring functional APC resistance. FVIII-R571S is being investigated as a potential high-potency therapeutic candidate for the treatment of hemophilia A, demonstrating enhanced hemostatic efficacy in vivo compared to wild-type FVIII.
- Other names
- Arg571Ser FVIIIArg-571Ser FVIIIArg 571Ser FVIIIArg590Ser FVIIIArg-590Ser FVIIIArg 590Ser FVIIIFactor VIII AuroraFVIII AuroraFVIII-R590SFVIII-R-590SFVIII-R 590S
02
Targets
APC (Activated protein C)Coagulation Factor IXaF10 (Factor Xa)F9 (Coagulation Factor IX)
Beyond the preview
Go deeper on FVIII-R571S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FVIII-R571S.